Clearside Biomedical, Inc.
NASDAQ:CLSD
1.23 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8.226 | 1.327 | 29.575 | 7.894 | 2.173 | 0.03 | 0.345 | 0.52 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.422 | 0.204 | 0.178 | 0 | 0 | 0 | 0 | 0 | 0.033 | 0 | 0 | 0 |
| Gross Profit
| 7.804 | 1.123 | 29.397 | 7.894 | 2.173 | 0.03 | 0.345 | 0.52 | -0.033 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.949 | 0.846 | 0.994 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 20.779 | 19.63 | 18.537 | 15.073 | 15.658 | 68.291 | 49.053 | 19.455 | 10.762 | 6.692 | 5.045 | 2.354 |
| General & Administrative Expenses
| 11.869 | 11.77 | 11.665 | 10.756 | 16.819 | 14.684 | 9.7 | 6.263 | 6.555 | 3.131 | 2.011 | 1.575 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.182 | 0 |
| SG&A
| 11.869 | 11.77 | 11.665 | 10.756 | 16.819 | 14.684 | 9.7 | 6.263 | 6.555 | 3.131 | 2.193 | 1.575 |
| Other Expenses
| 1.719 | 0.669 | 1.003 | -0.275 | -0.466 | 0.127 | -0.567 | -0.684 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 32.648 | 31.4 | 30.202 | 25.829 | 32.477 | 82.975 | 58.753 | 25.718 | 17.317 | 9.823 | 7.238 | 3.929 |
| Operating Income
| -24.844 | -30.277 | -0.627 | -17.935 | -30.304 | -82.945 | -58.408 | -25.198 | -17.317 | -9.823 | -7.238 | -3.929 |
| Operating Income Ratio
| -3.02 | -22.816 | -0.021 | -2.272 | -13.946 | -2,764.833 | -169.299 | -48.458 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -7.641 | -2.67 | 1.003 | -0.275 | -0.466 | 0.127 | -0.567 | -0.684 | -0.322 | -0.366 | -0.016 | -0.002 |
| Income Before Tax
| -32.485 | -32.947 | 0.376 | -18.21 | -30.77 | -82.818 | -58.975 | -25.882 | -17.639 | -10.189 | -7.254 | -3.931 |
| Income Before Tax Ratio
| -3.949 | -24.828 | 0.013 | -2.307 | -14.16 | -2,760.6 | -170.942 | -49.773 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.101 | 1.124 | -0.059 | -0.18 | -0.211 | 0.127 | -0.182 | -0.065 | 0.008 | 0.005 | 0.007 | 0 |
| Net Income
| -32.485 | -34.071 | 0.376 | -18.03 | -30.559 | -82.818 | -58.975 | -25.882 | -17.639 | -10.189 | -7.254 | -3.931 |
| Net Income Ratio
| -3.949 | -25.675 | 0.013 | -2.284 | -14.063 | -2,760.6 | -170.942 | -49.773 | 0 | 0 | 0 | 0 |
| EPS
| -0.53 | -0.57 | 0.006 | -0.39 | -0.8 | -2.69 | -2.33 | -1.97 | -1.44 | -0.83 | -0.59 | -4.67 |
| EPS Diluted
| -0.53 | -0.57 | 0.006 | -0.39 | -0.8 | -2.69 | -2.33 | -1.97 | -1.44 | -0.83 | -0.59 | -4.67 |
| EBITDA
| -24.777 | -29.608 | -0.449 | -17.935 | -30.304 | -82.945 | -58.408 | -25.198 | -17.249 | -9.785 | -7.216 | -3.922 |
| EBITDA Ratio
| -3.012 | -22.312 | -0.015 | -2.272 | -13.946 | -2,764.833 | -169.299 | -48.458 | 0 | 0 | 0 | 0 |